New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD

Luis M. Seijo, Joan B. Soriano, Germán Peces-Barba

Source: Eur Respir J, 53 (6) 1900717; 10.1183/13993003.00717-2019
Journal Issue: June
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 3
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Luis M. Seijo, Joan B. Soriano, Germán Peces-Barba. New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD. Eur Respir J, 53 (6) 1900717; 10.1183/13993003.00717-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhaled corticosteroid use and the incidence of lung cancer in COPD
Source: Eur Respir J, 55 (2) 1901720; 10.1183/13993003.01720-2019
Year: 2020



Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study
Source: Eur Respir J, 53 (6) 1801257; 10.1183/13993003.01257-2018
Year: 2019



Combination therapy of inhaled corticosteroids and long-acting beta2-agonists may be associated with risk reduction of lung cancer in COPD patients who quit smoking
Source: Eur Respir J 2006; 28: Suppl. 50, 454s
Year: 2006

The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD
Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019
Year: 2019



COPD and lung cancer incidence in never smokers
Source: International Congress 2019 – Asthma and COPD comorbidities
Year: 2019



Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis
Source: Eur Respir J, 54 (1) 1900778; 10.1183/13993003.00778-2019
Year: 2019



Inhaled immunotherapy for lung cancer? Certainly possible.
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018

COPD in patients with lung cancer and smoking
Source: Eur Respir J 2005; 26: Suppl. 49, 519s
Year: 2005

Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021


COPD, asthma, and lung cancer patients
Source: International Congress 2016 – ME13 Smoking cessation in difficult population groups
Year: 2016



Lung disease induced by newer therapies for lung cancer: an update
Source: Annual Congress 2006 - Drug-induced lung injury – new aspects
Year: 2006


New and emerging targeted treatments in advanced lung cancer
Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management
Year: 2016


Lung nodules in a lung cancer screening program: incidence density of lung cancer in patients with COPD and/or emphysema
Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Year: 2009


Management of concomitant COPD in patients with lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018

New and anticipated therapeutic developments in management of non-small-cell lung cancer
Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer
Year: 2013


Emphysema, COPD and lung cancer screening. Update of an ongoing study
Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer
Year: 2012


Incidence of lung cancer among COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 494s
Year: 2005

Common therapeutic approaches in IPF and lung cancer
Source: Research Seminar 2015
Year: 2015


Risk factors for lung cancer in COPD
Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer
Year: 2017